• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多灶性和弥漫性功能性甲状腺自主性放射性碘治疗的剂量改进概念

Improved dose concept for radioiodine therapy of multifocal and disseminated functional thyroid autonomy.

作者信息

Reinhardt M, Emrich D, Krause T, Bräutigam P, Nitzsche E, Blattmann H, Schümichen C, Moser E

机构信息

Department of Nuclear Medicine, University of Freiburg, Germany.

出版信息

Eur J Endocrinol. 1995 May;132(5):550-6. doi: 10.1530/eje.0.1320550.

DOI:10.1530/eje.0.1320550
PMID:7749494
Abstract

The present study analyzes the improvement of the outcome of radioidine therapy in non-immunogenic hyperthyroidism by adapting the target dose to the 99mTc-pertechnetate thyroid uptake under suppression (TcTUs) prior to radioiodine therapy. The TcTUs is a substitute for the non-suppressible iodine turnover. The 89 patients presented with a basal thyrotropin level of < 0.1 mU/l, normal values for free triiodothyronine and thyroxine and with multifocal or disseminated thyroid autonomy. These terms describe the scintigraphic distribution pattern of autonomous iodine turnover. Thirty-two patients had a TcTUs between 1.6 and 3.2% (group A) and 57 had a TcTUs > 3.2% (group B). Fifty-five patients (three of group A and 52 of group B) were treated previously for overt hyperthyroidism with antithyroid drugs. Target doses of 150 and 200 Gy were used in both groups and 300 Gy in group B only. Six months after radioiodine therapy, a basal TSH level of > or = 0.5 mU/l as criterion of therapy success was observed in 94% of group A and in 54% of group B. Further differentiation of group B shows an increasing success rate with the target dose used: 45% after 150 Gy, 50% after 200 Gy and 90% after 300 Gy. In patients with a basal TSH level of < 0.5 mU/l after radioiodine therapy, the TcTUs was evaluated again.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本研究通过在放射性碘治疗前根据抑制状态下的99m锝高锝酸盐甲状腺摄取量(TcTUs)调整目标剂量,分析了非免疫性甲状腺功能亢进症放射性碘治疗效果的改善情况。TcTUs可替代不可抑制的碘周转率。89例患者基础促甲状腺激素水平<0.1 mU/l,游离三碘甲状腺原氨酸和甲状腺素值正常,且存在多灶性或弥漫性甲状腺自主性。这些术语描述了自主性碘周转率的闪烁扫描分布模式。32例患者的TcTUs在1.6%至3.2%之间(A组),57例患者的TcTUs>3.2%(B组)。55例患者(A组3例,B组52例)此前曾用抗甲状腺药物治疗显性甲状腺功能亢进症。两组均使用150和200 Gy的目标剂量,B组仅使用300 Gy。放射性碘治疗6个月后,A组94%和B组54%的患者观察到基础促甲状腺激素水平≥0.5 mU/l作为治疗成功的标准。B组的进一步分析显示,随着所用目标剂量的增加成功率提高:150 Gy后为45%,200 Gy后为50%,300 Gy后为90%。放射性碘治疗后基础促甲状腺激素水平<0.5 mU/l的患者,再次评估TcTUs。(摘要截断于250字)

相似文献

1
Improved dose concept for radioiodine therapy of multifocal and disseminated functional thyroid autonomy.多灶性和弥漫性功能性甲状腺自主性放射性碘治疗的剂量改进概念
Eur J Endocrinol. 1995 May;132(5):550-6. doi: 10.1530/eje.0.1320550.
2
[First results of radioiodine therapy of multifocal and disseminated thyroid gland autonomy and use of a TcTUs-adapted dose concept].[多灶性和弥漫性甲状腺自主性的放射性碘治疗的初步结果及采用适配TcTUs的剂量概念]
Nuklearmedizin. 1998;37(6):192-6.
3
Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake.基于99m锝-高锝酸盐甲状腺摄取情况,对伴有多灶性和弥漫性自主性的边缘性甲状腺功能亢进患者进行放射性碘治疗的剂量选择。
Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):480-5. doi: 10.1007/s00259-001-0722-0. Epub 2002 Jan 29.
4
[Results of TcTUs-optimized radioiodine therapy in multifocal and disseminated autonomy].[多灶性和弥漫性自主性中经TcTUs优化的放射性碘治疗结果]
Nuklearmedizin. 1999;38(5):131-9.
5
Radioiodine therapy for Plummer's disease based on the thyroid uptake of technetium-99m pertechnetate.基于高锝[99mTc]酸盐甲状腺摄取的放射性碘治疗毒性弥漫性甲状腺肿。
Eur J Nucl Med. 2000 Sep;27(9):1286-91. doi: 10.1007/s002590000285.
6
[Radioiodine therapy of functional autonomy of the thyroid gland. Treatment results in view of pretreatment scintigraphic diagnosis and early response of triiodothyronine levels to treatment].[甲状腺功能自主性的放射性碘治疗。基于治疗前闪烁显像诊断及三碘甲状腺原氨酸水平对治疗的早期反应的治疗结果]
Med Klin (Munich). 1999 Aug 15;94(8):415-24. doi: 10.1007/BF03044725.
7
Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy?根据高锝[99mTc]酸盐的甲状腺摄取情况为临界甲状腺功能亢进患者选择放射性碘治疗剂量:对单灶性甲状腺自主性的适用性?
Eur J Nucl Med Mol Imaging. 2006 May;33(5):608-12. doi: 10.1007/s00259-005-0051-9. Epub 2006 Mar 16.
8
[Radioiodine therapy of funcitonal autonomy using the functional autonomous volume].[利用功能性自主体积进行功能性自主性的放射性碘治疗]
Nuklearmedizin. 1995 Aug;34(4):135-40.
9
[Change of 99m technetium-pertechnetate uptake by the thyroid under suppression (TcTus) induced by optimization of iodine supply in Germany].[德国通过优化碘供应诱导的甲状腺抑制下高锝酸盐摄取变化(TcTus)]
Nuklearmedizin. 1998;37(6):202-7.
10
TcTU before and after exogeneous TSH suppression in diagnosing thyroid autonomy.外源性促甲状腺激素抑制前后的锝-99m 高锝酸盐摄取试验在诊断甲状腺自主性方面的应用
Acta Med Austriaca. 1990;17 Suppl 1:54-5.

引用本文的文献

1
The route of administration (oral vs intravenous) does not influence dose or outcome in Graves' disease and unifocal autonomy.给药途径(口服与静脉注射)对格雷夫斯病和单灶自主性甲状腺结节的剂量或治疗结果没有影响。
Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):788-93. doi: 10.1007/s00259-005-1769-0. Epub 2005 Mar 10.
2
Abstracts of the Congress of the European Association of Nuclear Medicine. 25-29 August 2001, Napoli, Italy.欧洲核医学协会大会摘要。2001年8月25日至29日,意大利那不勒斯。
Eur J Nucl Med. 2001 Aug;28(8):961-1298. doi: 10.1007/BF02832651.
3
[Radioiodine therapy of functional autonomy of the thyroid gland. Treatment results in view of pretreatment scintigraphic diagnosis and early response of triiodothyronine levels to treatment].
[甲状腺功能自主性的放射性碘治疗。基于治疗前闪烁显像诊断及三碘甲状腺原氨酸水平对治疗的早期反应的治疗结果]
Med Klin (Munich). 1999 Aug 15;94(8):415-24. doi: 10.1007/BF03044725.
4
An update on diagnostic methods in the investigation of diseases of the thyroid.甲状腺疾病诊断方法的最新进展
Eur J Nucl Med. 1996 May;23(5):587-94. doi: 10.1007/BF00833398.